In an interview with pharmaphorum, Jennifer Lee, director of health economics, market access and reimbursement and advocacy at Janssen Cilag, said the company welcomes the evolution of the CDF ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...

Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC: Beerse, Belgium Tuesday, Dec ...

Belgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has ...

Johnson & Johnson subsidiary Janssen Pharmaceutica has licensed a range of drug candidates to BenevolentAI, a UK-based artificial intelligence company. The deal will make use of BenevolentAI’s ...

Erik Johnsen has been reimbursed by the Eli Lilly company and the Janssen-Cilag company for attending conferences. Igne Sinkeviciute has been reimbursed by the Pfizer company for attending a ...

When a lupus advocacy organization contacted the Janssen Pharmaceutical Companies of Johnson & Johnson to share findings that suggested one of the company’s existing approved medicines might be ...

These resources include the Janssen Business Development group and, under the umbrella of Johnson & Johnson Innovation, the company’s incubators JLABS and JPODS, innovation centers located in ...

BEERSE, BELGIUM, Nov. 14, 2024 (GLOBE NEWSWIRE) -- – Janssen-Cilag International NV, a Johnson & Johnson company, today announced results from additional analyses of the Phase 2 DAHLIAS study ...